Table 3

Demographic and clinical features of patients with NHL.

Demographic and baseline clinical features	N=21 (%)
Gender, female/male, N (%)	9/12 (42.9/57.1)
Age, median (range)	69 (53–84)
Types of NHL
Mantle cell lymphoma, N (%)	7 (33.4)
Diffuse large B-cell lymphoma, N (%)	5 (23.8)
Marginal zone lymphoma, N (%)	4 (19.0)
Waldenström macroglobulinemia, N (%)	3 (14.3)
Follicular lymphoma, N (%)	2 (9.5)
High prognosis score, N (%)	14 (66.7)
ECOG performance score≥3, N (%)	8 (38.1)
Bulky lesion, N (%)	4 (19.0)
Ann Arbor stage≥3, N (%)	20 (95.2)
Presence of B symptoms, N (%)	10 (47.6)
N of previous treatments
1	9 (42.9)
2	9 (42.9)
3	3 (14.2)
Previous treatment regimens
R-CHOP/CHOP	20 (95.2)
R-bortezomib/bortezomib	5 (23.8)
R-CVP/CVP	3 (14.2)
Diğer	7 (33.4)
Treatment duration with ibrutinib, median (range)	4 (1–28)
Patient requiring dose reduction, N (%)	3 (14.3)
Side effect of grade≥3 during treatment with ibrutinib	5 (23.8)
Treatment-emergent lymphocytosis, N (%)	2 (9.5)
Hb (g/dL), median (range)	11.8 (7.6–14.6)
Platelet (10³/mL), median (range)	165,000 (16,000–492,000)
WBC (10³/mL), median (range)	8,400 (3,200–157,800)
LDH U/L, median (range)	257 (105–437)
Creatinine clearance (mL/min/1.73 m²), median (range)	64 (26–120)